Kai Yuen Pharmaceutical Limited

Yes. In statutory due diligence and corporate verification, Kai Yuen Pharmaceutical Limited is authenticated as a lawful Private company limited by shares established on 2016-01-26 under the Companies Ordinance (Cap. 622) (duration: 10 years). Official registry indices confirm its current standing as [Live / In Operation] with active corporate capacity (Last verified: September 2026).

Official Hong Kong government registers assign two statutory identifiers to Kai Yuen Pharmaceutical Limited: 1. Business Registration Number (BRN / UBI): [65741233] (statutory identifier for tax and commercial registration under Cap. 310); 2. Company Registration Number (CRN): [2335207] (statutory filing number under Cap. 622). Commercial counterparties should verify both numbers on contracts and invoices.

In Hong Kong corporate compliance and banking KYC due diligence, verifying the decision-makers of Kai Yuen Pharmaceutical Limited requires cross-checking three statutory filings: 1. Latest Annual Return (Form NAR1) for issued share capital and shareholder equity percentages; 2. Form ND2A (Notice of Change of Company Secretary and Director) for interim board changes after the annual return date; and 3. Significant Controllers Register (SCR) penetration for natural persons or holding entities exercising ultimate control (UBO).

In Hong Kong corporate registration records, Kai Yuen Pharmaceutical Limited has officially logged 10 statutory image filing(s) since incorporation (latest statutory filing indexed on 2026-02-02: Form NAR1 - Annual Return (2026) (English)). Key authenticated filings include the latest Annual Return (Form NAR1 pursuant to Cap. 622 Section 662 - recording verified capital allocation, registered address, and director registers), original Incorporation documents (Form NNC1), and constitutional records, all authenticated with official ICRIS / e-Registry barcodes.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Chinese Medicine Regulatory Office (CMRO) (Licence No. PW-2018-00012); Department of Health (DH Licensed Dealer) (Licence No. 5/2A/2018); Department of Health (DH Licensed Dealer) (Licence No. 1/7A/2018); 2. Judicial Screening (Litigation & Winding-Up): screened against Hong Kong Judiciary cause books and winding-up registers under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32), with zero public compulsory winding-up petitions (HCCW) or civil litigation dockets currently indexed.

The statutory registered office of Kai Yuen Pharmaceutical Limited is registered at: [ROOM F, 9/F, WONG KING INDUSTRIAL, BUILDING, 2 TAI YAU STREET, SAN PO KONG, HONG KONG]. In accordance with Cap. 622 Section 658 and Cap. 622B Section 3, this Hong Kong address serves as the statutory venue for inspection of statutory registers, service of government and judicial process, and mandatory display of the corporation's full legal name.

Before entering into cross-border trade, credit settlement, or joint venture agreements with Kai Yuen Pharmaceutical Limited (CRN: 2335207 / 8-digit BRN: 65741233), standard institutional due diligence under Hong Kong law comprises four core verifications: 1. Standing & Identifier Match: Cross-checking active status under Cap. 622 and its 8-digit BRN under Cap. 310; 2. Equity & Signatory Penetration: Inspecting the latest Annual Return (Form NAR1) and Form ND2A to verify paid-up share capital, shareholders, and authorized signatory directors; 3. Register of Charges Screening: Checking Form NM1 filings under Part 8 (Section 334) of Cap. 622 for pledged corporate assets or bank floating charges; and 4. Judicial Screening: Verifying the absence of High Court winding-up petitions (HCCW) or civil litigation writs.